New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 18, 2014
07:46 EDTTKMRTekmira initiated with an Outperform at Leerink
Target $25.
News For TKMR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 19, 2015
14:33 EDTTKMRTekmira main driver still hepatitis B program, says Leerink
Subscribe for More Information
09:18 EDTTKMROn The Fly: Pre-market Movers
Subscribe for More Information
08:01 EDTTKMRTekmira provides update on TKM-Ebola-Guinea
Tekmira Pharmaceuticals announced that the Phase II clinical trial of TKM-Ebola-Guinea has reached a predefined statistical endpoint and enrollment has been closed. The endpoint indicated that continuing enrollment was not likely to demonstrate an overall therapeutic benefit. Data analysis is ongoing and the full results will be made available as soon as possible. In this trial, TKM-Ebola-Guinea is being evaluated for efficacy in Ebola virus infected patients in Sierra Leone, West Africa. The Phase II single arm trial called RAPIDE, or Rapid Assessment of Potential Interventions & Drugs for Ebola, is open-label with a concurrent observational study of Ebola virus disease in Sierra Leone.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use